The potential use of disease-fighting technology developed at AlphaVax is expanding.

The RTP-based vaccine technology company said Tuesday that it is expanding its licensing agreement with Harrisvaccines, which targets a variety of animal diseases.

Financial terms were not disclosed.

AlphaVax has raised more than $80 million in venture capital and partner funding.

The company has proprietary technology for producing vaccines based on modified alphaviruses. Alphaviruses are defined by the Centers for Disease Control and Prevention as RNA-containing viruses that are often found in mosquito-transmitted diseases.

Harrisvaccines, which is based in Ames, iowa, said it would use AlphaVax technology to include “all companion animals diseases” beyond lifestock animals such as swine, poultry, cattle, horses and aquatic animals raised on farms.

Among the targets is respiratory diseases in dogs.

“This is a significant milestone for Harrisvaccines and solidifies our place as an innovative leader in the biologics industry with the ability to utilize this novel, exclusive technology in all preventive veterinary aspects,” said Joel Harris, head of sales and marketing for Harrisvaccines.

The firm already targets specific viruses using genetic sequencing as part of its RNA Particle Platform.